Pre‐fibrotic/early primary myelofibrosis vs. WHO‐defined essential thrombocythemia: The impact of minor clinical diagnostic criteria on the outcome of the diseaseGeorg Jeryczynski, Heinz Gisslinger, Jürgen Thiele et al.|American Journal of Hematology|2017Cited by 66
Clinical impact of bone marrow morphology for the diagnosis of essential thrombocythemia: comparison between the BCSH and the WHO criteriaHeinz Gisslinger, J. Thiele, A-I Schiefer et al.|Leukemia|2015Cited by 62
Essential thrombocythemia vs. pre-fibrotic/early primary myelofibrosis: discrimination by laboratory and clinical dataMartin Schalling, Heinz Gisslinger, Andreas Gleiß et al.|Blood Cancer Journal|2017Cited by 20
ROP-ET: a prospective phase III trial investigating the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythemia patients with limited treatment optionsJean‐Jacques Kiladjian, Christoph Klade, Francisca Ferrer‐Marín et al.|Annals of Hematology|2024Cited by 14
Austrian recommendations for the management of primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis: an expert statementThamer Sliwa, Heinz Gisslinger, Christine Beham‐Schmid et al.|Wiener klinische Wochenschrift|2016Cited by 9